Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects

Clinical Pharmacokinetics

Volumn 46, Issue 9, 2007, Pages 767-775

  Tianmei, Si ^a   Knadler, Mary Pat ^b   Lim, Ming T ^c   Kwee, Poo Yeo ^c   Teng, Leyan ^c   Liang, Shu ^a   Pan, Alan X ^c   Lobo, Evelyn D ^b  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE;

ADULT; APPETITE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NAUSEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TANDEM MASS SPECTROMETRY; VITAL SIGN; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHINA; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; NAUSEA; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; THIOPHENES; VOMITING;

EID: 34548355186     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746090-00004     Document Type: Article

References (19)

1. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005; 27 (8): 1126-43
2. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11 (12): 1475-93
3. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14 (6): 457-70
4. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003; 170 (4 Pt 1): 1259-63
5. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6 (5): 346-56
6. Eli Lilly and Company. Cymbalta® (duloxetine hydrochloride) delayed-release capsules [US package insert; online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/021427s009s011s013lbl.pdf [Accessed 2007 Jul 19]
7. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119 (1-3): 5-15
8. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003; 31 (9): 1142-50
9. Kuo F, Gillespie TA, Kulanthaivel P, et al. Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett 2004; 14 (13): 3481-6
10. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73 (3): 170-7
11. Hua TC, Pan A, Chan C, et al. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2004; 57 (5): 652-6
12. Bradford LD, Kirlin WG. Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. Int J Neuropsychopharmcol 1998; 1 (2): 173-85
13. Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res 2003; 23 (1): 31-5
14. Landi MT, Sinha R, Lang NP, et al. Human cytochrome P4501A2. IARC Sci Publ 1999; (148): 173-95
15. Chan C, Yeo KP, Pan AX, et al. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol 2007; 63 (3): 310-4
16. Ma N, Zhang B, Li H, et al. Determination of duloxetine in human plasma via LC/MS and subsequent application to a pharmacokinetic study in healthy Chinese volunteers. Clinica Chimica Acta 2007; 380: 100-5
17. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000; 40 (2): 161-7
18. Bartoli A, Xiaodong S, Gatti G, et al. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 1996; 18 (5): 586-91
19. Eli Lilly and Company. Cymbalta (duloxetine hydrochloride) capsules. Clinical pharmacology biopharmaceutics review, part 2: 20 [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/021427_s000_Cymbalta.htm [Accessed 2007 Aug 9]